Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06138561 · ClinicalTrials.gov registry record
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
A clinical trial of Bladder Cancer and Urothelial Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 180
- Enrollment target
- 1
- Study location
NCT06138561 is a study of Bladder Cancer and Urothelial Carcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 180 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06138561, a study of Bladder Cancer and Urothelial Carcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.
Conditions Studied
Interventions
- BEHAVIORAL Geriatric-8 Survey
- BEHAVIORAL National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)
- BEHAVIORAL Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-03-05 |
| Est. Completion | 2028-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06138561
The ClinicalTrials.gov registry entry for NCT06138561 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Geriatric-8 Survey is the first listed.
NCT06138561 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06138561 about?
NCT06138561 is a clinical study titled "Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments". The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its a...
What is the current status of trial NCT06138561?
This trial is currently recruiting. The enrollment target is 180 participants. The study started on 2024-03-05. Estimated completion is 2028-01-01.
What conditions does trial NCT06138561 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma.
What interventions are being tested in trial NCT06138561?
The interventions under investigation include: Geriatric-8 Survey (BEHAVIORAL), National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) (BEHAVIORAL), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06138561?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06138561 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.